Aberrant regulation of type I collagen gene expression is a hallmark of the fibrotic disorders which are often associated with rheumatoid arthritis. The long term objective of this proposal is to formulate a comprehensive conceptual framework to precisely delineate the DNA-protein interactions which underlie transcriptional regulation of the human Proalpha(I) collagen gene. The more immediate goal will be the molecular dissection of the cis- regulatory sequence motifs that comprise the Proalpha1(I) promoter/enhancer and the trans-acting factors which interact with these sequences. Chimeric collagen promoter/enhancer-reporter gene constructs will be introduced into cultured cells of mesenchymal and non-mesenchymal origin by transient or stable transfection protocols, and also incorporated into the genome of transgenic mice; the expression of the reporter gene will be assessed and compared between in vitro and in vivo models. Putative trans-acting factors involved in the constitutive and modulatory transcriptional regulation of the Proalpha1(I) gene will be extensively characterized and cDNA encoding these factors will be molecularly cloned. Mechanisms by which interactions between the cis-elements and the trans-acting factors ensure appropriate transcriptional regulation of the human Proalpha1(I) gene will be studied by cotransfection of the target promoter/enhancer- reporter constructs and expression vectors containing the putative trans- acting factor(s). Additionally, cell-free systems will be developed to investigate the detailed protein-DNA interactions which determine Proalpha1(I) collagen transcription. These studies will unravel the molecular interactions that orchestrate appropriate tissue and cell specificity of transcriptional regulation of human Proalpha1(I) collagen gene expression. A detailed understanding of the mechanisms of transcriptional control of type I collagen genes will enable us to devise therapeutic interventions to reduce the articular and extraarticular fibrotic manifestations associated with rheumatoid arthritis.

Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2013) Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. J Immunol 190:5382-91
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2010) An autoantigen-specific, highly restricted T cell repertoire infiltrates the arthritic joints of mice in an HLA-DR1 humanized mouse model of autoimmune arthritis. J Immunol 185:110-8
Tang, Bo; Zhou, Jing; Park, Jeoung-Eun et al. (2009) T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol 133:145-53
Myers, Linda K; Tang, Bo; Rosioniec, Edward F et al. (2007) An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol 27:345-56
Ye, X J; Tang, B; Ma, Z et al. (2007) The effects of interleukin-18 on rat articular chondrocytes: a study of mRNA expression and protein synthesis of proinflammatory substances. Clin Exp Immunol 149:553-60
Rosloniec, Edward F; Brandstetter, Tilmann; Leyer, Sigmar et al. (2006) Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun 27:182-95
Ahn, Jae I; Erdin, Robert A; Smith, Richard et al. (2006) Chondrocyte injection in distraction epiphysiolysis (rabbit model). J Orthop Res 24:355-65
Rosloniec, Edward F; Ivey 3rd, Robert A; Whittington, Karen B et al. (2006) Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol 177:3884-92
Sakurai, Yoshihiko; Tang, Bo; Rosloniec, Edward F et al. (2006) Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar. Immunology 117:136-42
Sakurai, Yoshihiko; Brand, David D; Tang, Bo et al. (2006) Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther 8:R150

Showing the most recent 10 out of 122 publications